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Abstract
Adaptive enrichment designs involve rules for restricting enrollment to a subset
of the population during the course of an ongoing trial. This can be used to target
those who benefit from the experimental treatment. To leverage prognostic informa-
tion in baseline variables and short-term outcomes, we use a semiparametric, locally
efficient estimator, and investigate its strengths and limitations compared to standard
estimators. Through simulation studies, we assess how sensitive the trial performance
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†Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA,
21205.
‡Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging
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writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.
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(Type I error, power, expected sample size, trial duration) is to different design char-
acteristics. Our simulation distributions mimic features of data from the Alzheimer’s
Disease Neuroimaging Initiative, and involve two subpopulations of interest based on
a generic marker. We investigate the impact of the following design characteristics:
the accrual rate, the delay time between enrollment and observation of the primary
outcome, and the prognostic value of baseline variables and short-term outcomes. We
apply information-based monitoring, and evaluate how accurately information can be
estimated in an ongoing trial.
Keywords: multiple testing procedure; treatment effect heterogeneity
1 Introduction
Adaptive enrichment designs involve pre-planned rules for restricting enrollment based on
accrued data in an ongoing trial (Wang et al., 2007). If, for example, a subpopulation
shows evidence of no benefit of treatment, its enrollment could be stopped while the com-
plementary subpopulation continues to be enrolled. Stallard et al. (2014) give an overview
of statistical methods for adaptive enrichment designs, including the p-value combination
approach (Bretz et al., 2006; Schmidli et al., 2006; Jennison and Turnbull, 2007; Brannath
et al., 2009); the conditional error function approach (Friede et al., 2012); and approaches
using group sequential computations (Stallard, 2011; Magnusson and Turnbull, 2013). We
use an adaptive enrichment design from the general class of Rosenblum et al. (2016), which
is based on the group sequential computation approach.
We consider trials where the primary outcome is observed a fixed amount of time from
enrollment (called the delay). To illustrate, we use data from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) study. We set the primary outcome to be a measure of change
in severity of dementia symptoms from baseline to 1 year of follow-up described below; this
is similar to the primary outcome in an ongoing, phase 3 clinical trial of a drug to slow cogni-
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tive and functional decline from early Alzheimer’s Disease (Biogen, 2016). Also recorded are
baseline variables and the short-term outcome of change in severity of dementia symptoms
measured at 6 months of follow-up.
To leverage prognostic information in baseline variables and the short-term outcome,
we use a semiparametric, locally efficient estimator (called the adjusted estimator, for con-
ciseness) from van der Laan and Gruber (2012). The adjusted estimator in a randomized
trial is consistent under mild regularity conditions without requiring any parametric model
assumptions. It has potential to improve precision, power, expected sample size, and trial
duration when variables are sufficiently prognostic for the outcome. In trials with delayed
outcomes, the adjusted estimator uses information from pipeline participants, i.e., enrollees
whose primary outcome has not yet been observed.
An open question is how useful the above estimators are in adaptive enrichment designs
with delayed outcomes, under different configurations of delay, accrual rates and prognostic
value. We use simulation studies that mimic features of data from the ADNI study, and
examine the impact of delay, accrual rates, prognostic baseline variables, and prognostic
short-term outcomes.
The simulated trials involve multiple stages, and information-based monitoring is used to
determine the time of interim analyses. We evaluate the accuracy of information estimates
when using the adjusted estimator versus the unadjusted estimator, which is critical in order
that the familywise Type I error be controlled.
In Section 2 we describe the ADNI study. In Section 3 we present notation. The simula-
tion setup is given in Section 4. Section 5 presents simulation results, including the impact of
prognostic baseline variables and a short-term outcome (Section 5.1), the impact of varying
delay time (Section 5.2), and the impact of varying the accrual rates (Section 5.3) on the
performance of the adaptive design. In Section 6 we discuss information accrual rates and
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how accurately these can be estimated in an ongoing trial. Section 7 discusses limitations
and future research directions.
2 Data Example
Our simulations are based on distributions that mimic features of the data from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI), an observational longitudinal study of cognitive
impairment and progression to Alzheimer’s disease. The ADNI was initiated in 2003 as a
public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The pri-
mary goal of the study has been to test whether serial magnetic resonance imaging, positron
emission tomography, other biological markers, and clinical and neuropsychological assess-
ment can be combined to measure the progression of mild cognitive impairment and early
Alzheimer’s disease.1 The Clinical Dementia Rating (CDR) scale is used to assess the sever-
ity of dementia symptoms and provides both a numeric global score ranging from 0 to 3,
and a sum of boxes (SOB) score ranging from 0 to 18.
Our data come from 286 patients who entered the ADNI study with mild cognitive
impairment (CDR 0.5 with a SOB score 2.5 or less) and who remained in the study for
the full 12 months of follow-up. For conciseness, we refer to the sum of the CDR global
score and the SOB score as the CDR score. We define the primary outcome Y as the
difference between the CDR score at baseline and at 12 months. We define the short-term
outcome L as the difference between the CDR score at baseline and at 6 months. Let W
denote the following five prognostic baseline variables: CDR score at baseline; age; Aβ42
(a type of amyloid plaque involved in Alzheimer’s disease progression); Alzheimer’s Disease
Association (ADA, 13 items) scale; and the Mini Mental State Examination (MMSE) score.
We consider two distinct subpopulations defined by apolipoprotein E (APOE) 4 carrier
1For up-to-date information, see www.adni-info.org.
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status. Subpopulation 1 consists of those with no 4 alleles, and subpopulation 2 consists of
those with at least one 4 allele. (no alleles being subpopulation 1 vs. at least one allele being
subpopulation 2). Among the 286 patients, 47% carry no APOE 4 alleles. We consider a
hypothetical treatment whose goal is to delay the progression of disease. Since we had more
measurements at 12 and 24 months in the dataset, but we wanted to use the timescale of 6
and 12 months in our simulated trial, we mapped each 12- and 24-month outcome to 6-and
12-month, respectively, throughout our paper.
3 Notation
When followed up completely, each participant i in the trial has full data vector Di =
(Si,Wi, Ai, Li, Yi). We use the vector D = (S,W,A, L, Y ) when referring to a generic par-
ticipant. The variable Si ∈ {1, 2} denotes the subpopulation that participant i belongs to;
Wi denotes a vector of baseline variables; Ai denotes the treatment assignment indicator;
Li denotes the short-term outcome; and Yi denotes the primary outcome. We assume that
(Si,Wi, Ai) are observed when participant i is enrolled, and that Li and Yi are observed at
duration dL and dY , respectively, from the time of enrollment, with dL ≤ dY . Each vector Di
is assumed to be an independent, identically distributed draw from an unknown distribution
Q, with the only restriction being that A is randomized by design with equal probability of
being 0 or 1, independent of S,W . The short-term outcome L can be any predefined mea-
surement made after randomization. No assumptions on its relationship to Y are needed
in order that our estimators (adjusted and unadjusted) are consistent and asymptotically
normal.
For a given population, the average treatment effect is defined to be the difference between
the population mean of the primary outcome under treatment (A = 1) versus control (A = 0).
Denote the average treatment effect in subpopulation 1, subpopulation 2, and the combined
5
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population by ∆1, ∆2, and ∆0, respectively, where ∆0 = E(Y |A = 1)−E(Y |A = 0) and for
each subpopulation s ∈ {1, 2}, ∆s = E(Y |A = 1, S = s)−E(Y |A = 0, S = s). Let ps denote
the proportion of subpopulation s in the combined population. Then ∆0 = p1∆1 + p2∆2.
Define the null hypotheses
H01 : ∆1 ≤ 0; H02 : ∆2 ≤ 0; H00 : ∆0 ≤ 0,
which represent no average treatment benefit in subpopulation 1, subpopulation 2, and the
combined population, respectively.
We quantify the prognostic value of W and L for explaining variance in the primary
outcome Y for the combined population. Define the R-squared of W and R-squared of L as
R2W =
var{E(Y | W )}
var(Y )
, R2L =
var{E(Y | L)}
var(Y )
. (1)
R2W represents the fraction of variance in Y explained by W . Similarly, R
2
L represents the
fraction of variance in Y explained by L.
Using the ADNI study data, we approximated (1) to roughly determine how much of the
variance of the outcome Y is explained by W or L. The empirical R2W is computed as in
(1), with E(Y | W ) estimated by a linear model with intercept and main terms W3,W4, and
the variances are estimated by the empirical variance. (We use only W3,W4 in the working
model for constructing the adjusted estimator; see Section 4.2.) A similar computation was
done to obtain the empirical R2L replacing W by L. The resulting values are 0.20 and 0.48
for R2W and R
2
L, respectively. Roughly speaking, this indicates both variables are moderately
to strongly prognostic for Y .
We estimated R2W and R
2
L within each subpopulation, and found the prognostic values
differ by subpopulation. The corresponding empirical R2W is 0.30 for subpopulation 1 and
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0.14 for subpopulation 2; the empirical R2L is 0.44 for subpopulation 1 and 0.50 for subpop-
ulation 2. This differential prognostic value by subpopulation impacts information accrual
and power for the adjusted estimator as described in Section 5. In what follows, R2W and
R2L refer to (1) for the combined population.
4 Simulation Setup
4.1 Overview
Our goal is to evaluate the performance of an adaptive enrichment design with a delayed
outcome when we vary the prognostic values in baseline variables and short-term outcome,
accrual rates, delay time, and estimator used. The performance is evaluated based on Type
I error, power, expected sample size and average duration of the trial, and is based on
two estimators: the unadjusted estimator (the difference between the sample means of the
primary outcome between the two study arms), and an adjusted estimator that leverages
baseline variables and the short-term outcome. The latter is a targeted maximum likelihood
estimator (TMLE) of van der Laan and Gruber (2012) implemented in the R package ltmle
(Schwab et al., 2015). The R code we used for the adjusted estimator is provided in the
Supplementary Materials. We also could have used adjusted estimators such as those of
Lu and Tsiatis (2011); Rotnitzky et al. (2012); Gruber and van der Laan (2012). Both the
unadjusted and adjusted estimators are consistent and asymptotically normal under mild
regularity conditions (van der Laan and Gruber, 2012).
We vary the following in our simulation studies: the prognostic value of baseline variables
W and short-term outcome L represented by the R-squared formulas in Section 3; the delay
time dL to observe the short-term outcome; the delay time dY to observe the final outcome;
and the accrual rate.
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4.2 Data Generating Distributions Based on ADNI Data
Hypothetical trials are populated with participants, each of whose data vector D is drawn
independently from a data generating distribution Q, which may differ by simulation study.
We constructe each Q to mimic certain observed relationships between W , L and Y within
each subpopulation s ∈ {1, 2} in the ADNI study. For simplicity, we center W within each
subpopulation S.
Since there is no treatment in the ADNI study, we assign the treatment variable A in-
dependent of S,W , and having a relationship with Y as described next. The minimum,
clinically meaningful, average treatment effect for our hypothetical trials is δmin = 0.42,
which corresponds to a 30% relative improvement in mean CDR score change, i.e., a 30%
reduction in disease progression. Within each of our five simulation studies (described be-
low), we generate data under four treatment effect settings (abbreviated as “effect setting”
hereafter): (a) treatment benefits neither subpopulation (∆1 = ∆2 = 0); (b) treatment ben-
efits subpopulation 1 only (∆1 = δmin,∆2 = 0); (c) treatment benefits subpopulation 2 only
(∆1 = 0,∆2 = δmin); and (d) treatment benefits both subpopulations (∆1 = ∆2 = δmin).
Effect settings (b) and (c) involve treatment effect heterogeneity.
The data generating distribution in each set of simulations is denoted by
Q = Q
(
∆1,∆2, R
2
W , dY , accrual rate, L measured, R
2
L, dL
)
,
and is determined by the following: the pair of treatment effects for each subpopulation
(∆1,∆2); the prognostic value of the baseline covariates R
2
W ; the delay between enrollment
and the primary outcome dY ; the accrual rate; whether the short-term outcome L is mea-
sured and if so, its prognostic value R2L and delay time dL from enrollment. We set the
enrollment process to be random, where the enrollment time of the patients follows a ho-
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mogeneous Poisson process with intensity equal to the accrual rate. We assume that each
subpopulation’s accrual rate is proportional to its prevalence in the combined population.
In each simulation study, we vary one or several of the above at a time to assess the impact
on trial performance.
First, consider the case where the short-term outcome L is not measured. Within each
subpopulation S = s, Y is drawn from the linear model:
Y = βs0 + β
s
WW + β
s
AA+ Y , Y ∼ N
(
0, (σsY )
2
)
(2)
with Y independent of (W,A). The values β
s
0, β
s
W and σ
s
Y are based on the above model fit
to the ADNI study data separately within each stratum S = s and leaving out A. We set
βsA = ∆s to be the desired treatment effect, which depends on the effect settings (a)-(d).
For the case where L is measured, within each subpopulation S = s, Y and L are
generated from the linear models:
L = αs0 + α
s
WW + α
s
AA+ L, L ∼ N
(
0, (σsL)
2
)
(3)
Y = βs0 + β
s
WW + β
s
AA+ β
s
LL+ Y , Y ∼ N
(
0, (σsY )
2
)
(4)
with Y and L independent of (W,A) and of each other. The values of β
s
0, β
s
W , β
s
L, σ
s
Y , α
s
0,
αsW and σ
s
L are based on the above models fit to the ADNI study data separately within each
stratum S = s and leaving out A. For simplicity we set αsA = 0, and set β
s
A = ∆s to be the
desired treatment effect. The β values in (4) are not the same as those in (2); however, we
do not distinguish between these in our notation, when there is no ambiguity as to whether
L is measured in the simulation scenario.
We construct simulation distributions with a range of R2W and R
2
L values by varying α
and β. We do so in such a way that the average treatment effect within each subpopulation
9
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is unchanged, and the variance of Y within each subpopulation and each treatment arm
is unchanged; our method is summarized below with details given in the Supplementary
Material. The result is that the (asymptotic) performance of the unadjusted estimator is
unchanged, providing a benchmark to compare against. In simulation scenarios where L is
not measured, to change the prognostic value of W we multiply the original fits of β1W , β
2
W
from the ADNI study data by a tuning parameter pW in (2), and change σ
s
Y accordingly so
that the variance of Y given A, S and the average treatment effect given S are unchanged. In
simulation scenarios where L is measured, to change the prognostic value of L, we multiply
β1L, β
2
L by pL in (4) and change σ
s
Y accordingly to ensure that the variance of Y given A, S
and the average treatment effect given S are unchanged. These modifications do not affect
the unadjusted estimator, although they do impact the adjusted estimator (as we will show
in Section 5).
Let the default simulation scenario be the one with design characteristics corresponding
to the empirical distribution of the ADNI study data: R2W = 0.20, R
2
L = 0.48; the default sce-
nario sets dL = 0.5 years, dY = 1 year, and the accrual rate for the combined population to be
334 patients/year. We conduct 5 sets of simulations with various design characteristics that
are summarized in Table 1. Each combination of (R2W , dY , accrual rate, L measured, R
2
L, dL)
is referred to as a simulation scenario. For example, in simulation study 1 (row 1 in Ta-
ble 1), R2W is varied from 0 to 0.6, the short-term outcome is not measured, and all other
characteristics are set to the default value.
In all simulations, we use the full set of baseline covariates (W1,W2,W3,W4,W5) in the
data generating distributions (2)-(4) for L and Y , but we only include baseline variables
W3, W4 (Aβ42 and ADA) in the working models used by the adjusted estimator. We in-
tentionally induced such model misspecification, since in practice the working models used
by the adjusted estimator will generally be misspecified. In addition, the TMLE estimator
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Table 1: Summary of setups for 5 simulation studies. Default value of pa-
rameter: R2W = 0.20, R
2
L = 0.48, dL = 0.5 years, dY = 1 year, accrual rate
334 patients/year. Ranges of values x− y indicate the design characteristic(s)
varied in the corresponding simulation study.
Simulation
study
R2W dY (yrs)
accrual rate
(patients/year)
L measured R2L dL (yrs)
1 0− 0.6 default default No NA NA
2 0 default default Yes 0− 0.6 default
3 default 0− 2 default No NA NA
4 default 0.05, 0.5, 1, 1.5, 2 default Yes default 0− dY
5 default default 100− 1000 Yes default default
uses logistic regression working models (by first scaling the outcome to the interval [0, 1])
rather than linear models, which can lead to additional misspecification. Though the ad-
justed estimator is robust to the above model misspecification in that it is still consistent
and asymptotically normal, the misspecification may reduce its precision.
4.3 Adaptive Enrichment Design
We define a new adaptive enrichment design using the general framework developed by
Rosenblum et al. (2016). We consider two subpopulations: S = 1 if the patient has no
APOE 4 allele, and S = 2 if the patient has one or more APOE 4 allele. Define S = 0
to be the combined population. We consider an adaptive enrichment design with maximum
number of stages K = 5. At each analysis k ≤ K, let Zs,k denote the Wald statistic
(estimator divided by its standard error) for null hypothesis H0s, s ∈ {0, 1, 2}. For each
population s and stage k ≤ K, let us,k denote the efficacy boundary for the null hypothesis
H0s (s ∈ {0, 1, 2}), and let ls,k denote the futility stopping boundary (s ∈ {1, 2}). The
multiple testing procedure at each analysis k ≤ K consists of the following steps:
1. For each s ∈ {1, 2}, if subpopulation s has not had enrollment stopped at a previous
analysis, and if Zs,k > us,k, reject H0s.
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2. For each s ∈ {1, 2}, if H0s is rejected or Zs,k < ls,k, stop subpopulation s enrollment.
3. If both H01 and H02 are rejected, or (if both subpopulations have not had enrollment
stopped at a previous analysis and Z0,k > u0,k), reject H00.
The trial continues until both subpopulations terminate enrollment or the final analysis K
is reached.
Define the power of H01 to be the probability to reject at least H01 under effect setting
(b), power of H02 to be the probability to reject at least H02 under effect setting (c), and
power of H00 to be the probability to reject at least H00 under effect setting (d). The design’s
goals are to achieve at least 80% power to reject the corresponding null hypothesis under
each effect setting (b), (c), and (d), and to strongly control the familywise Type I error rate
at level 0.025, asymptotically. For example, the requirement under effect setting (b) is 80%
power for H01.
The Type I error spent at each stage, futility boundaries ls,k, s ∈ {1, 2}, 1 ≤ k ≤ K
and the information level (inverse of the estimator’s variance) used for analysis timing are
in Table 2. They were constructed by approximately solving the following optimization
problem: for the unadjusted estimator under the default simulation scenario, minimize the
expected sample size averaged over effect settings (a)-(d), subject to the Type I error and
power constraints in the previous paragraph. The optimization was solved using an approach
from Fisher and Rosenblum (2016), and does not necessarily equal the true optimum solution
(which is currently an open research question). The asymmetry in the solution is because the
proportion p1 = 0.47 and the variances differ by subpopulation. In determining the values
of efficacy boundaries us,k, s ∈ {0, 1, 2}, 1 ≤ k ≤ K, we use the error spending approach
as described in Rosenblum et al. (2016, Section 3.2), which extends the approach of Slud
and Wei (1982); Lan and DeMets (1983) to multiple populations; see the Supplementary
Material for details. These efficacy boundaries depend on the covariance matrix of the
12
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estimator being used. The design is guaranteed to strongly control the familywise Type I
error rate at level 0.025, asymptotically, for Wald statistics based on either the unadjusted
or adjusted estimators.
Table 2: Adaptive enrichment design, and efficacy boundaries under default
simulation scenario.
Analysis (k) 1 2 3 4 5
Type I error spent for Subpop. 1 0.0007 0.0007 0.0028 0.0015 0.0038
Type I error spent for Subpop. 2 0.0001 0.0023 0.0012 0.0026 0.0027
Type I error spent for Comb. Pop. 0.0028 0.0006 0.0009 0.0013 0.0012
Futility boundary (l1,k) -4.12 0.40 -1.48 0.94 -
Futility boundary (l2,k) -0.10 0.29 0.42 0.93 -
Information threshold for Subpop. 1 13.0 20.2 24.9 40.1 69.1
Information threshold for Subpop. 2 13.4 20.2 25.7 41.1 69.6
Information threshold for Comb. Pop. 27.1 40.8 50.1 80.3 138.5
Efficacy boundaries for the unadjusted estimator under default simulation scenario
Effcacy boundary (u1,k) 3.12 3.06 2.64 2.77 2.53
Effcacy boundary (u2,k) 3.52 2.76 2.78 2.63 2.62
Effcacy boundary (u0,k) 2.78 3.08 2.92 2.86 2.89
4.4 Analysis Timing and Information Accrual
We present our method to determine the time of each analysis based on information mon-
itoring. Consider either the adjusted or unadjusted estimator. There are 3 populations of
interest (the two subpopulations and the combined population) in our design. For each pop-
ulation there is a treatment effect estimator whose variance changes over time as patients
are continuously enrolled. We define the information accrued for each population as the
reciprocal of the corresponding estimator’s variance. The kth analysis occurs at the earliest
time when the information accrued for every population is above its corresponding, preset
threshold (which is a preset function of the Type I error allocated at that stage, i.e., part of
13
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the trial design). Information thresholds in the design, shown in Table 2, were set such that
for the unadjusted estimator in the default simulation scenario, the information accrual for
each population crosses its threshold at the same calendar time. Information can accrue at
different rates depending on whether the unadjusted or adjusted estimator is used, as shown
in our simulations. Faster information accrual can lead to earlier analyses in calendar time
and usually smaller sample size at each analysis.
Since in practice the variance of each estimator is unknown, one could use a variance
estimator that is updated whenever new data accrues. (See Section 6 where we investigate the
accuracy of information estimation at given time points.) However, it is not computationally
feasible to implement this in our simulations where each data generating distribution is used
to simulate 10,000 trials. Instead, we set analysis timing once for each simulation scenario
and estimator type, using an approximation described in the Supplementary Material.
Table 3 shows the calendar times of each analysis for the unadjusted and the adjusted
estimators under the default simulation scenario. The cumulative sample size at each analysis
time is random due to the random accrual process; Table 3 is an example realization. Time
of analysis and sample sizes are substantially smaller for the adjusted estimator compared
to the unadjusted due to the former having a faster information accrual rate.
5 Results
We simulated 10,000 trials for each simulation scenario and effect setting combination. Table
4 shows the empirical probability of rejecting each hypothesis under the four effect settings
in the default simulation scenario. The numbers with * indicate Type I error, i.e., rejecting
at least one true null hypothesis. Under effect setting (a), all null hypotheses are true; under
effect setting (b) (or (c)), only H01 (or H02) is true; under effect setting (d), none of the null
hypotheses are true.
14
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Table 3: Calendar time to conduct interim analysis for unadjusted and ad-
justed estimators under default simulation scenario. For one realization of the
trial we show the cumulative sample size (CSS) with the format: number of
participants with Y observed (+ number of pipeline participants). If no early
stop occurs, “stop enroll” column shows the time of last participant enrolled,
and we wait until all participants have Y observed then conduct the final
analysis (analysis 5).
Analysis (k) 1 2 3 4 stop enroll 5 (final)
Unadjusted estimator
Time (years) 2.2 2.8 3.2 4.5 6.1 7.1
CSS (Subpop. 1) 108 (+245) 202 (+252) 275 (+248) 479 (+237) 730 (+238) 968 (+0)
CSS (Subpop. 2) 104 (+290) 241 (+257) 309 (+256) 528 (+248) 788 (+275) 1063 (+0)
CSS (Comb. Pop.) 212 (+535) 443 (+509) 584 (+504) 1007 (+485) 1518 (+513) 2031 (+0)
Adjusted estimator
Time (years) 1.8 2.3 2.7 3.8 5.1 6.1
CSS (Subpop. 1) 54 (+251) 137 (+238) 192 (+245) 375 (+236) 585 (+222) 807 (+0)
CSS (Subpop. 2) 53 (+276) 133 (+283) 223 (+257) 415 (+258) 626 (+242) 868 (+0)
CSS (Comb. Pop.) 107 (+527) 270 (+521) 415 (+502) 790 (+494) 1211 (+464) 1675 (+0)
Across all the simulation scenarios we considered, the familywise Type I error rate was
always controlled at 0.025 for both adjusted and unadjusted estimators. All the power goals
in Section 4.3 are met. For the unadjusted estimator, the powers of H00, H01 and H02 (defined
in Section 4.3) are all between 80% − 83% under different simulation scenarios. This is as
expected due to our method of determining the analysis timing (as described in Section 4.4).
For the adjusted estimator, the power of H02 also stays near 80% under different simulation
scenarios, whereas the power of H01 and H02 can be much higher than 80% under certain
simulation scenarios, e.g. when the prognostic value in W is considerably high (R2W > 0.3).
This is because R2W is always higher in subpopulation 1 than in subpopulation 2 due to the
way we vary pW in Section 4.2. (See Section A.3 for a more detailed discussion.) If one
intended to have exactly 80% power for all three hypotheses for the adjusted estimator, we
could have optimized a separate adaptive design for the adjusted estimator to incorporate
the different R2W in two subpopulations. However, this would make it harder to do a head-
to-head comparison of the unadjusted and the adjusted estimators.
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Table 4: Type I error / power for two estimators under default simulation
scenario. Type I errors (numbers with *) are computed assuming nonbinding
futility boundaries; powers are computed assuming binding futility boundaries.
In “Percent probability to reject”, to reject an individual hypothesis means to
reject at least that hypothesis; All/Any means to reject all/any of the three
hypotheses. The empirical values corresponding to the power requirements are
in bold for each scenario (b)-(d).
Effect setting Percent probability to reject
H00 H01 H02 All Any
(a) ∆1 = ∆2 = 0 0.7* 1.0* 1.1* 0.0* 2.5*
Adjusted (b) ∆1 = δmin,∆2 = 0 12 87 1.1* 1.0* 88
estimator (c) ∆1 = 0,∆2 = δmin 16 1.1* 80 0.9* 80
(d) ∆1 = ∆2 = δmin 83 88 80 70 98
(a) ∆1 = ∆2 = 0 0.6* 1.0* 1.1* 0.0* 2.5*
Unadjusted (b) ∆1 = δmin,∆2 = 0 12 82 1.0* 0.9* 82
estimator (c) ∆1 = 0,∆2 = δmin 15 1.1* 81 1.0* 81
(d) ∆1 = ∆2 = δmin 82 81 81 66 97
In what follows, we focus on comparing the expected sample size (ESS) and the expected
duration (ED) as summaries of trial performance under different simulation scenarios and
between the two estimators.
5.1 Simulation Studies 1-2: Effect of Prognostic Value of Baseline Variables
and Short-term Outcome
Figure 1 illustrates how ESS and ED are affected when one of R2W or R
2
L varies. The
performance of the unadjusted estimator remains the same when the prognostic value in W
and L changes, providing a benchmark to compare with. The adjusted estimator performs
similar to the unadjusted when there is no prognostic value in W or L, i.e. R2W = R
2
L = 0.
As R2W or R
2
L increases, the adjusted estimator leverages this to achieve faster information
accrual and fewer participants per stage, which leads to smaller ESS and ED. In simulation
study 1, R2W is varied from 0 to 0.6; in simulation study 2, R
2
L is varied from 0 to 0.6 (Table
1).
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Our results indicate that for the adjusted estimator, a prognostic baseline variable is
more valuable than an equally prognostic short-term outcome in terms of reducing ESS and
ED. For instance, under effect setting (d), increasing R2W from 0 to 0.25 results in a 19%
drop in ESS, whereas increasing R2L from 0 to 0.25 only renders a 2% drop. This is because
all enrolled patients’ baseline variables contribute to the precision of the adjusted estimator;
however, although the short-term outcome of every participant is used, the efficiency gain
from adjusting for L is proportional to the number of participants in the pipeline (i.e., those
who have L but not Y observed). Moreover, a participant’s baseline variables potentially
improve precision for estimation of both E(Y |A = 1) and E(Y |A = 0), while a participant’s
short-term outcome is only used toward improving precision for one of these, corresponding
to the treatment that participant received.
5.2 Simulation Studies 3-4: Effect of Delay Times dY and dL
We assess the impact of delay times dY and dL on the performance of the design. In simulation
study 3, we vary dY from 0 years (immediate Y ) to 2 years with L not measured. In
simulation study 4, with L measured we set dY to several levels, and in each case vary dL
from 0 (immediate L) to dY .
Figure 2 shows the comparison under simulation study 3. ESS and ED increase with
longer dY for both estimators. This is intuitive: the longer it takes to observe the primary
outcome, the more time is needed to accumulate the necessary information. The adjusted
estimator leads to smaller ESS and ED than the unadjusted estimator uniformly over all
values of dY because of gains from adjusting for baseline variables W . In addition, ESS and
ED for both estimators are approximately linear in dY .
Figure 3 shows the comparison under simulation study 4. When dY is fixed, the perfor-
mance of the unadjusted estimator remains the same regardless of the length of dL, because
17
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Figure 1: Left: impact of R2W on ESS and duration in simulation study 1.
Right: impact of R2L on ESS and duration in simulation study 2. Since the
results corresponding to unadjusted estimator do not change as R2W and R
2
L
are varied, they are marked only once next to the vertical axis using the circle,
square, diamond, and triangle symbols. δ refers to δmin.
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L is not used in the unadjusted estimator. For the adjusted estimator, a longer dL results in a
smaller proportion of pipeline participants who have L observed—hence, slower information
accrual and larger ESS and ED. Even when dL = dY , which implies no asymptotic precision
gain from adjusting for L, the adjusted estimator still gains from adjusting for prognostic
W .
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Figure 2: Impact of dY on ESS and ED in simulation study 3. Different line
types indicate the ESS and ED under four effect settings. For the adjusted
estimator, the lines for ED under effect settings (b)-(d) are clustered together.
For the unadjusted estimator, the lines for ED under effect settings (b) and
(c) are clustered together. δ refers to δmin.
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Figure 3: Effect of dY and dL on ESS and ED in simulation study 4. Since the
results corresponding to unadjusted estimator do not change when dL varies
as long as dY is fixed, they are marked only once next to the vertical axis using
the circle, square, diamond, and triangle symbols. δ refers to δmin.
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5.3 Simulation Study 5: Effect of Accrual Rate
Figure 4 illustrates how the ESS and ED are affected by different accrual rates. Because the
information depends either entirely (for the unadjusted estimator) or largely (for the adjusted
estimator) on the number of participants who have the delayed outcome Y observed, with
faster accrual there will generally be more pipeline participants at interim analyses. These
additional pipeline participants make ESS larger. On the other hand, ED gets shorter with
faster accrual. The impact of accrual rate on ESS and ED is similar across the two estimators.
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Figure 4: Impact of accrual rate on ESS and ED. Different line types indicate
the ESS and ED under four effect settings. For each estimator, the curves for
ED under effect settings (b)-(d) are clustered together. δ refers to δmin.
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6 Information Accrual Rates and Estimating Information Levels
In Section 4.4 we presented our approach for determining the time for analyses based on
information monitoring. Here we explore information accrual more thoroughly and discuss
how accurately information can be estimated in an ongoing trial. At each time, we are
interested in two types of information level: the current information, i.e., the inverse of
variance of the estimator computed using available data at the time, and the wait-for-pipeline
information, i.e., the inverse of variance of the estimator using available data at the time
plus the not yet observed L and Y of the pipeline participants. The current information is
used for determining time for interim analyses, and the wait-for-pipeline information is used
for determining time for the final analysis when we wait until all pipeline participants finish
the trial and then test hypotheses.
Figure 5(a) shows how the two types of information accrue over time for the two estima-
tors under the default simulation scenario when enrollment is not stopped.
For the unadjusted estimator, the information at a given time is proportional to the
number of patients with Y observed; for the adjusted estimator, such proportionality is
only approximate because the pipeline participants also contribute information. There is an
approximately constant gap between the current information and the wait-for-pipeline infor-
mation for each estimator, because the extra information in the not yet observed outcomes
from the pipeline participants stays roughly constant over time. The adjusted estimator
results in a faster information accrual compared to the unadjusted estimator, which is con-
sistent with better trial performance (as shown in Section 5). The information accrual rates
do not depend on ∆1,∆2 since in our setup these do not impact the estimator’s variance.
In practice, one needs a reliable method for estimating the information level using data
from the ongoing trial in order to determine information-based timing for interim and final
analyses. The sample variance is used to estimate the true variance of the unadjusted
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estimator. For the adjusted estimator, its variance can be estimated using the nonparametric
bootstrap or by the influence curve. The ltmle package computes an influence-curve-based
variance estimate (ICVE) for the TMLE estimator. ICVE can be conservative in the sense
that it may overestimate the variance (van der Laan and Gruber, 2012); in our simulation,
however, it approximates the variance quite well.
Figure 5(b) summarizes the performance of the variance estimators under the default
simulation scenario. The solid red line connects the true information levels over time, and
the box-plots represent the distribution of ICVE at 5 analyses assuming no early stopping.
The mean and the spread of the distribution of ICVE increase with time (and hence with
sample size n), because the information level is approximately n times the reciprocal of the
variance of the estimator’s influence curve, and the latter is estimated with standard error
proportional to n−1/2 asymptotically. Therefore, the spread in the box plots representing
the approximate interquartile range grows at rate n1/2. A similar observation applies to the
sample variance estimate for the unadjusted estimator. Estimation accuracy for information
accrual is similar for the two estimators.
7 Discussion
In simulation studies 3 and 4 in Section 5.2, we set constant prognostic values R2W and R
2
L,
while varying dL and dY . It may also be of interest to consider a range of simulation scenarios
where the prognostic value changes with delay. For example, it is possible that with longer
dY , the baseline variables W become less correlated with the final outcome Y , e.g., if these
variables measure the same quantity at different time points. In addition, if dL is closer to
dY then the correlation between L and Y may be stronger. It is an area of future research to
explore such simulation scenarios, in which there is a trade-off such that shorter dL means
more participants will have L but not Y observed, but such L is less prognostic for Y .
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(b) Box-plots of estimated information level for adjusted estimator (using influence-curve-based
method) and unadjusted estimator (using sample variance) at each of the five analyses assuming
no early stopping of enrollment (so that enrollment stops dY = 1 year before the final analysis;
see Table 3). The red solid line connects the true information levels, and each box-plot shows the
spread of the estimated information level.
Figure 5: Information accrual rates and box-plots of estimated variance for
the adjusted and unadjusted estimators under the default simulation scenario.
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We used the full set of baseline variables (W1, . . . ,W5) in generating data, and only used
(W3,W4) in the adjusted estimator. Since model misspecification is likely to occur in practice,
we think it is important to have incorporated this in our simulation study. We could also
include subpopulation information S as a baseline variable in estimating the treatment effect
for the combined population with the adjusted estimator. Another potential modification
would be to separately optimize the trial design for the adjusted estimator (rather than use
the same information-based design that was optimized for the unadjusted estimator). These
modifications could further increase the gains due to adjustment.
In (3) we set αA = 0, i.e., the treatment doesn’t affect the short-term outcome. Setting
this to be nonzero could impact efficiency gains from prognostic L.
Open research problems include investigating the impact of subpopulation proportion,
and generalizing the findings to other designs and data generating mechanisms. Another
problem is to evaluate the impact of dropout in the simulation. The adjusted estimator can
provide advantages over the unadjusted estimator for handling dropout under the missing
at random assumption, in which case the unadjusted estimator will typically be inconsistent
(van der Laan and Gruber, 2012).
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A Supplementary Material
A.1 Detail for varying prognostic values in the data generating mechanism
The fitted α, β and σ’s from the ADNI study data are shown in Table 5.
Table 5: Fitted α, β and σ’s from the ADNI study data
L is not measured
s = 1 s = 2
βs0 -1.131 -1.664
βsW1 0.007 0.172
βsW2 -0.027 0.013
βsW3 0.001 -0.007
βsW4 -0.148 -0.111
βsW5 0.027 0.150
σsY 1.552 1.773
L is measured
s = 1 s = 2 s = 1 s = 2
βs0 -0.699 -0.808 α
s
0 -0.485 -0.734
βsW1 -0.134 0.140 α
s
W1
0.158 0.028
βsW2 -0.011 0.009 α
s
W2
-0.018 0.003
βsW3 -0.002 -0.006 α
s
W3
0.004 -0.001
βsW4 -0.098 -0.031 α
s
W4
-0.057 -0.068
βsW5 -0.017 0.099 α
s
W5
0.049 0.043
βsL 0.890 1.167
σsY 1.247 1.342 σ
s
L 1.044 0.996
In varying R2W and R
2
L as described in Section 4.2, it is desired that the average treat-
ment effect within each subpopulation remains unchanged, and the variance of Y given A, S
remains unchanged. This implies that E(Y | A = 1, S = s)−E(Y | A = 0, S = s), s ∈ {1, 2}
and var(Y | A = a, S = s) for a ∈ {1, 2} and s ∈ {1, 2} need to be unchanged. Throughout
rest of the subsection we omit the superscript s, because the following procedures will be
conducted separately within each of the subpopulations.
In simulation scenarios where L is not measured, we multiply βW by a tuning parameter
pW in (2). The mean and variance of Y given A = a become:
E(Y | A = a) = β0 + βAa, (5)
var(Y | A = a) = var(pWβWW ) + var(Y )
= p2Wβ
T
Wvar(W )βW + σ
2
Y . (6)
E(Y | A = a) does not depend on pW , and neither does the average treatment effect. For a
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given pW , we solve for σ
2
Y so that the value of (6) is constant under different specifications
of pW . R
2
W with A = 0 defined in (1) becomes:
R2W =
p2Wβ
T
Wvar(W )βW
var(Y | A = 0) . (7)
In simulation scenarios where L is measured, we multiply βL by a tuning parameter pL
in (4). The mean and variance of Y given A = a become:
E(Y | A = a) = β0 + pLα0βL + βAa, (8)
var(Y | A = a) = var{(βW + pLαWβL)W}+ var(Y + pLβLL)
= (βW + pLαWβL)
Tvar(W )(βW + pLαWβL) + σ
2
Y + p
2
Lβ
2
Lσ
2
L, (9)
The average treatment effect does not depend on pL. For a given pL, we solve for σ
2
Y so that
the value of (9) is constant under different specifications of pL. R
2
L with A = a defined in
(1) becomes:
R2L =
p2Lβ
2
Lvar(L)
var(Y | A = a) . (10)
A.2 Algorithm to Compute Efficacy Boundaries us,k
At stage k for the null hypothesis H0s, 1 ≤ k ≤ K, s ∈ {0, 1, 2}, denote αs,k as the Type
I error to be spent, and us,k the efficacy boundary for the Wald statistic Zs,k (estimator
divided by its standard deviation). Define the ordering (s′, k′) ≺ (s, k) if and only if k′ < k
or (k′ = k and s′ < s). Define us,k to be the solution to
P {Zs′,k′ ≤ us′,k′ for all (s′, k′) ≺ (s, k), and Zs,k > us,k | ∆1 = ∆2 = 0} = αs,k,
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where the joint distribution of Zs,k is approximated by a normal distribution, with variance-
covariance matrix estimated from 10,000 simulated trials.
A.3 Detail for Analysis Timing
For each fixed data generating distribution
Q = Q
(
∆1,∆2, R
2
W , dY , accrual rate, L measured, R
2
L, dL
)
and each estimator, our method to determine time of analyses consists of four steps:
Step 1: Generate 10,000 pilot simulated trials where interim analyses are conducted at
25 pre-selected calendar time points t1, . . . , t25, such that approximately 50 patients from
subpopulation 1 are enrolled between tj and tj+1. For each tj, we record the estimated treat-
ment effect τj at that time and the “wait-for-pipeline” treatment effect τ˜j that is obtained by
assuming enrollment is stopped at tj and estimating the treatment effect after Y is measured
for all pipeline participants.
Step 2: Compute the variances of τj and τ˜j from the 10,000 pilot simulated trials, the
inverse of which are the current information and wait-for-pipeline information at tj, respec-
tively.
Step 3: For interim analyses 1 - 4, linearly interpolate to find calendar time Tk of which
the current information equals that listed in Table 2 for the corresponding k ∈ {1, 2, 3, 4}.
For the final analysis, linearly interpolate to find the calendar time T5 of which the wait-for-
pipeline information equals that listed in Table 2 for k = 5.
Step 4: In the simulated trials, interim analyses 1 - 4 are conducted at calendar times
T1, . . . , T4, enrollment stops at T5 (if no early stopping occurs), and final analysis is conducted
at calendar time T5 + dY .
In step 3, for each k we identify the calendar time such that the information accrued for
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subpopulation 1, subpopulation 2 and the combined population all exceed the corresponding
threshold in Table 2. The design is optimized for the unadjusted estimator, so that when
using the unadjusted estimator, the thresholds for the three populations are crossed at
almost the same time. However, for the adjusted estimator, since W is more prognostic in
subpopulation 1 than in subpopulation 2 in the ADNI study data, by the time the information
accrued for subpopulation 2 reaches the threshold, information accrued for subpopulation 1
and the combined population already exceed their corresponding thresholds. Thus, for the
adjusted estimator at each interim analysis the information for subpopulation 2 is exactly
as in Table 2, whereas the information for subpopulation 1 and the combined exceeds the
thresholds in Table 2. This makes the power for H01 and H00 higher than 80% for the
adjusted estimator (as presented in Section A.4.1, Figure 6).
A.4 Additional Simulation Results
A.4.1 Impact of Prognostic Value, Delay Time and Accrual Rate on power
Figure 6 shows that for the adjusted estimator power of H01 and H00 increases with larger
R2W , whereas the power of H02 remains roughly constant. Change in R
2
L, dY , dL or accrual
rate does not substantially affect power. For the unadjusted estimator power is always
constant.
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Figure 6: Change in power under simulation studies 1-5. The power of
H00/H01/H02 is the probability to reject at least H00/H01/H02 under effect
setting (d)/(b)/(c). Since the results corresponding to unadjusted estimator
do not change as the design characteristics are varied, they are marked only
once next to the vertical axis using the circle, square, diamond, and triangle
symbols.
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